The object of this study was to evaluate the seasonality of gout in Korea. We retrospectively examined data from 330 patients seen at nine rheumatology clinics, treated with urate lowering therapy (ULT) more than one year after stopping prophylactic medication. Demographic data, clinical and laboratory features, and seasonality of gout onset and flares were collected. Season was classified in three-month intervals. The mean age was 52.2 yr and mean disease duration was 26.8 months. The male to female count was 318:12. The onset of acute gouty attacks was obtained in 256 patients. Gout developed most commonly in summer season (36.7%) (P<0.001) and in June (15.6%, P=0.002). During ULT, there were 147 (male 97.3%) gout flares. Although there was no statistically significant difference, gout flares were more common in summer (30.6%). Aggravating factors were identified in 57 flares: alcohol (72.0%) was most common. In the patients who attained target serum uric acid (<6 mg/dL) at the end of prophylaxis, gout flares were high in fall (35.8%) and September (17.0%). In Korea, the summer is most common season of gout onset and there is a tendency for gout flares to increase during ULT in summer/fall season.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330476 | PMC |
| http://dx.doi.org/10.3346/jkms.2015.30.3.240 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk Factors for Recurrence of Benign Paroxysmal Positional Vertigo: A Prospective Study.
Otol Neurotol
September 2024
Department of Otorhinolaryngology-Head and Neck Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Article Synopsis
- - The study focused on identifying demographic and clinical factors that lead to recurrences of benign paroxysmal positional vertigo (BPPV) in patients within a year of treatment.
- - Researchers analyzed data from 139 participants, finding that around 34.5% experienced at least one recurrence, with multiple treatments for the initial episode and a history of gout being significant risk factors.
- - The results highlight that a sizable portion of patients treated for BPPV may experience recurrences, emphasizing the need for better understanding and management strategies for those at higher risk.
Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged ≥50 years.
Semin Arthritis Rheum
October 2024
GSK, Rockville, MD, USA.
Article Synopsis
- This study aimed to determine if the recombinant zoster vaccine (RZV) increases the risk of developing new-onset gout in adults aged 50 and older in the US.
- Researchers analyzed health claims data for individuals who received RZV and checked for gout events within 60 days, using a self-controlled risk interval method to compare the risk during the first 30 days post-vaccine to the following 30 days.
- The results showed no significant difference in gout occurrences after vaccination, suggesting that RZV does not increase the risk of gout in the studied population.
Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged ≥65 years.
Semin Arthritis Rheum
October 2024
Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD, USA. Electronic address:
Objective: Assess the risk of incident gout following exposure to recombinant zoster vaccine (RZV).
Methods: This case-only, self-controlled risk interval study included a cohort of US fee-for-service Medicare (Part A, B, and D) beneficiaries aged ≥65 years. The exposure was receipt of at least one dose of the two-dose RZV regimen in 2018 or 2019.
Prospects of industrial membrane concentrates: treatment of landfill leachates by coupling reverse osmosis and wet air oxidation.
Environ Sci Pollut Res Int
February 2024
Aix Marseille Univ, CNRS, Centrale Méditerranée, M2P2, Marseille, France.
Stabilized landfill leachates are characterized by a high chemical oxygen demand and limited biodegradability. This study investigates the removal of the organic fraction (chemical oxygen demand and total organic carbon) using a treatment approach that couples membrane processes and wet air oxidation (operating at 200-300 °C and 18 MPa). The aim is to address the challenges posed by landfill leachate membrane concentrates considering variations throughout the year across three different seasons.
View Article and Find Full Text PDFSeasonal variations for newly prescribed urate-lowering drugs for asymptomatic hyperuricemia and gout in Japan.
Front Pharmacol
January 2024
Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Urate-lowering drugs (ULDs) have been approved for treatment of asymptomatic hyperuricemia and gout in Japan. Although serum urate levels and rates of gout onset are known to have seasonal variations, no survey results regarding the seasonality of ULD prescriptions for asymptomatic hyperuricemia and gout have been reported. A large-scale database of medical claims in Japan filed between January 2019 and December 2022 was accessed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!